Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Clin. Cancer Res 2021 Oct 29;[EPub Ahead of Print], Y Song, Q Gao, H Zhang, L Fan, J Zhou, D Zou, W Li, H Yang, T Liu, Q Wang, F Lv, H Guo, X Zhao, D Wang, P Zhang, Y Wang, L Wang, T Liu, Y Zhang, Z Shen, J Huang, J ZhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.